
TSS Name/#:



Specimens Submitted:

1: SP: Uterus, cervix, ovaries and fallopian tubes; total abdominal

hysterectomy and bilateral salpingo-cophorectomy

2: SP: Sentinel lymph node, oburator, left 3: SP: Sentinel lymph node, obturator, right

DIAGNOSIS:

1. SP: Uterus, cervix, ovaries and fallopian tubes; total abdominal hysterectomy and bilateral salpingo-cophorectomy:

Tumor Type:

Adenocarcinoma, endometrioid type

Architectural Grade (For Endometrioid Types only): II (6-50% solid growth)

Nuclear Grade (For Endometrioid Types only): Grade 2

FIGO Grade (For Endometrioid Types only): Grade 2

Myometrial Invasion:

(>50%)

Measures15mm in maximum depth

Myometrium thickness measures26mm in the area of maximal tumor invasion

Endocervical Invasion:

Not identified

Lymphovascular invasion:

Identified

Endometrium:

Exhibits complex hyperplasis with atypis

Myometrium:

Exhibits adenomyosis

Adnexa:

Unremarkable

SP: Sentinel lymph node, oburator, left: Lymph Node Dissection:

\*\* Continued on next page \*\*

UUID: 1E33ABA3-0855-4021-A370-DB8E2CA4C022 UUID: 1E33ABA3-0B55-4021-A3/0-DBBEZLA4C022 TCGA-AP-A1E4-01A-PR Redact Redacted

Criteria	Yes	No
Diagnosis Discrepancy		Y
Primary Tumor Site Discrepancy		7
HIPAA Discrepancy		1
Prior Malignancy History		7
Dual/Synchronous Primary Noted		7-7-
Case is (circle): JA QUALIFIED / Di	QUALIFIED	
Reviewer Initials Date Reviewed:	1211	
	<del></del>	
		· T

TSS Name/#:

Benign lymph nodes
Number of lymph nodes examined: 1
with endosalpingiosis

NOTE: IHMUNOHISTOCHEMICAL STAINS FOR CYTCKERATIN AE1/3 ARE NEGATIVE FOR
METASTATIC CARCINOMA, BUT HIGHLIGHT ENDOSALPINGIOSIS.

3. SP: Sentinel lymph node, obturator, right:
Lymph Node Dissection:
Benign lymph nodes
Number of lymph nodes examined: 2

NOTE: IMMUNOHISTOCHEMICAL STAINS FOR CYTCKERATIN AE1/3 ARE NEGATIVE FOR

I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED THIS REPORT.

METASTATIC CARCINOMA.

